Results 281 to 290 of about 52,496 (299)

Muscarinic Receptor Antagonists

Pulmonary Pharmacology & Therapeutics, 1999
N, Watson, R M, Eglen
openaire   +2 more sources

Selective muscarinic antagonists as bronchodilators.

Agents and actions. Supplements, 1992
The non-selective muscarinic antagonist ipratropium is widely used as bronchodilator. Due to its pharmacokinetic properties this drug, after inhalation, acts only locally on the airways and no unwanted anticholinergic side-effects are observed. Another approach is the use of selective muscarinic antagonists. Based on their selectivity for M3- and/or M1-
openaire   +1 more source

Muscarinic Antagonists

2010
Michael M. Morgan, MacDonald J. Christie, Thomas Steckler, Ben J. Harrison, Christos Pantelis, Christof Baltes, Thomas Mueggler, Markus Rudin, Lawrence H. Price, Malcolm Lader, R. H. Belmaker, Joseph H. Friedman, Peter Verhaert, Per Svenningsson, Per E. Andrén, Giovanni Hernandez, Peter Shizgal, Bart Ellenbroek, Trevor W. Robbins, Peter Verhaert, Per Svenningsson, Per E. Andrén, Paul Newhouse, Heather Wilkins, Lance R. McMahon, Luis Stinus, Stéphanie Caillé, Martine Cador, Mary E. Cain, Michael T. Bardo, Sarah Morgan, Angus Mackay, Lucio Tremolizzo, Gessica Sala, Carlo Ferrarese, Alfonso Abizaid, Shimon Amir, Alfonso Abizaid, Shimon Amir, Stephen M. Stahl, Meghan M. Grady, Theodora Duka, Rodrigo Andrade, Yesne Alici, William Breitbart, Debby Van Dam, Peter Paul De Deyn, Warren H. Meck, Catalin V. Buhusi, Malcolm Lader, Martine Cador, Marie-Louise G. Wadenberg, Tomek J. Banasikowski, Richard J. Beninger, Stefan Leucht, Kim Wolff, Peter Verhaert, Per Svenningsson, Per E. Andrén, Elizabeth C. Warburton, Anne M. Andrews, Greg A. Gerhardt, Lynette C. Daws, Johannes Mosbacher, Gabriele Fischer, Annemarie Unger, Martine Cador, Ian P. Stolerman, Seiya Miyamoto, Iain S. McGregor, Murray R. Thompson, Paul D. Callaghan, Trevor W. Robbins, Nachum Dafny, Bernard Le Foll, Theodora Duka, Albert Adell, Francesc Artigas, Anne M. Andrews, Greg A. Gerhardt, Lynette C. Daws, Roberto William Invernizzi, Ennio Esposito, Jelena Nesic, Theodora Duka, Yesne Alici, William Breitbart, Josef Marksteiner, Irene Adelt, Huaiyu Yang, George I. Papakostas, Malcolm Lader, Klaus A. Miczek, R. Hamish McAllister-Williams, Tomasz Schneider, Stephen B. Dunnett, Andrew Young, Klaus A. Miczek, Michael Minzenberg, W. Wolfgang Fleischhacker, Andrew Holt, Darrell D. Mousseau, Glen B. Baker, Stephen M. Stahl, Meghan M. Grady, Andreas Marneros, Guy M. Goodwin, Seiya Miyamoto, Mohammed Shoaib, Mitul A. Mehta, Seiya Miyamoto, Stephen C. Fowler, Joachim Liepert, Thomas R. E. Barnes, Christof Baltes, Thomas Mueggler, Markus Rudin, Ennio Esposito, Roberto William Invernizzi, Josee E. Leysen, Ben J. Harrison, Christos Pantelis, Ronald F. Mucha, Holden D. Brown, Michael E. Ragozzino, Michael E. Ragozzino, Holden D. Brown, Paul Newhouse, Heather Wilkins, R. Andrew Chambers   +129 more
openaire   +1 more source

Improved Muscarinic Antagonists as Anticholinesterase Antidotes

1990
Abstract : Muscarinic antagonists play an important role in anticholinesterase agent therapy by reducing the response of muscarinic receptors to acetylcholine, acting synergistically with cholinesterase reactivators. Therapy with antagonists such as atropine is difficult to manage because of the toxicity of these compounds, atropine antagonizes the ...
openaire   +1 more source

Muscarinic Antagonists

1993
Alan F. Casy, George H. Dewar
openaire   +1 more source

Long-acting muscarinic M3 receptor antagonists.

Expert opinion on therapeutic patents, 2010
A series of 10 closely related patent applications define Theravance's approach to the development of long-acting M(3) selective antagonists for the treatment of chronic obstructive pulmonary disease. The applications illustrate a modular approach to the design of such agents, comprising a muscarinic pharmacophore attached to a second, less ...
openaire   +2 more sources

Muscarinic receptor antagonists

Reactions Weekly, 2015
openaire   +1 more source

Dual-acting beta2 agonists/muscarinic antagonists.

Expert opinion on therapeutic patents, 2010
Bifunctional aromatic derivatives that act as both beta(2) agonists and muscarinic receptor antagonists are claimed. The compounds use two separate pharmacophoric groups, coupled by a long lipohilic chain, to provide the desired biological activities and with the aim of providing a long duration of action.
openaire   +1 more source

Muscarinic Receptor Antagonists

1998
openaire   +1 more source

Darifenacin, A selective muscarinic M3 antagonist

Pharmacological Research, 1995
R.M. Wallis, R.A. Burges, P.E. Cross, A.R. MacKenzie, D.T. Newgreen, P. Quinn   +5 more
openaire   +1 more source